Ingrid Rauter named CMO at Vaccentis

Vaccentis AG
Appointee name
Ingrid Rauter


Vaccentis AG of Switzerland has appointed Ingrid Rauter as chief medical officer and head of research and development to help oversee development of the company’s autologous vaccine pipeline which includes a vaccine for non-metastatic renal cell carcinomas following surgery. Dr Rauter joins Vaccentis from Amgen Inc where she led development of the company’s early inflammation pipeline. She also held clinical development roles at Takeda Pharmaceutical Co Ltd and Sandoz.

Vaccentis announced the appointment on 3 May 2023.

Copyright 2023 Evernow Publishing Ltd